• Snigdha Vallabhaneni, Alex Kallen, Sharon Tsay, Nancy Chow, Rory Welsh, Janna Kerins, Sarah K Kemble, Massimo Pacilli, Stephanie R Black, Emily Landon, Jessica Ridgway, Tara N Palmore, Adrian Zelzany, Eleanor H Adams, Monica Quinn, Sudha Chaturvedi, Jane Greenko, Rafael Fernandez, Karen Southwick, E Yoko Furuya, David P Calfee, Camille Hamula, Gopi Patel, Patricia Barrett, MSD, Patricia Lafaro, Elizabeth L Berkow, Heather Moulton-Meissner, Judith Noble-Wang, Ryan P Fagan, Brendan R Jackson, Shawn R Lockhart, Anastasia P Litvintseva, and Tom M Chiller.
• MMWR Morb. Mortal. Wkly. Rep. 2016 Nov 11; 65 (44): 1234-1237.

AbstractCandida auris, an emerging fungus that can cause invasive infections, is associated with high mortality and is often resistant to multiple antifungal drugs. C. auris was first described in 2009 after being isolated from external ear canal discharge of a patient in Japan (1). Since then, reports of C. auris infections, including bloodstream infections, have been published from several countries, including Colombia, India, Israel, Kenya, Kuwait, Pakistan, South Africa, South Korea, Venezuela, and the United Kingdom (2-7). To determine whether C. auris is present in the United States and to prepare for the possibility of transmission, CDC issued a clinical alert in June 2016 informing clinicians, laboratorians, infection control practitioners, and public health authorities about C. auris and requesting that C. auris cases be reported to state and local health departments and CDC (8). This report describes the first seven U.S. cases of C. auris infection reported to CDC as of August 31, 2016. Data from these cases suggest that transmission of C. auris might have occurred in U.S. health care facilities and demonstrate the need for attention to infection control measures to control the spread of this pathogen.

18 keywords...

hide…